4166.TWO Orient Pharma Co. Ltd.

Healthcare Pharmaceuticals Taiwan OTC Exchange
22.65 TWD
Close of Nov 5, 2026
22.00 29.60
Market cap
TWD 5.50B
P/E
23.1x
P/B
2.08x
ROE
7.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4166.TWO undervalued?

Graham number
Price22.65
Graham value15.48
Premium46.3%

4166.TWO trades 46.3% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Orient Pharma Co. Ltd. fundamental analysis

No fundamental analysis for Orient Pharma Co. Ltd. yet.

Orient Pharma Co. Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Orient Pharma Co. Ltd.

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

Full company profile